MeiraGTx

MeiraGTx

Yahoo Finance • 2 days ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 13 days ago

MeiraGTx GAAP EPS of $1.71 beats by $2.15, revenue of $321.4M

* MeiraGTx press release [https://seekingalpha.com/pr/20618173-meiragtx-reports-second-quarter-2026-financial-and-operational-results] (MGTX [https://seekingalpha.com/symbol/MGTX]): Q2 GAAP EPS of $1.71 beats by $2.15. * Revenue of $32... Full story

Yahoo Finance • 13 days ago

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

MeiraGTx Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerost... Full story

Yahoo Finance • last month

What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near

Stuart Naylor, the Chief Scientific Officer, Ophthalmology of MeiraGTx Holdings plc (NASDAQ:MGTX), sold 27,659 shares of ordinary shares on July 7, 2026, according to an SEC Form 4 filing. Transaction summary Metric Value Transaction val... Full story

Yahoo Finance • 2 months ago

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investment Following regulatory approval, Oberland Capital to receive low single-digit capped royalties on the net sales of each of AAV2-hAQP1 for... Full story

Yahoo Finance • 3 months ago

Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint

MeiraGTx Holdings PLC (NASDAQ:MGTX) is one of the best gene therapy stocks to buy in 2026. The stock has gained around 25% year-to-date and soared more than 95% over the past year. Looking ahead, analysts believe the stock could explode mo... Full story

Yahoo Finance • 3 months ago

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MeiraGTx Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia Entered into an asset pu... Full story

Yahoo Finance • 4 months ago

Here is Why MeiraGTx Holdings (MGTX) is One of the Best Growth Stocks Under $10

MeiraGTx Holdings (NASDAQ:MGTX) is one of the best growth stocks under $10 to invest in. On April 16, MeiraGTx Holdings entered into an asset purchase agreement with Johnson & Johnson to reacquire all interests in botaretigene sparoparvove... Full story

Yahoo Finance • 4 months ago

Evercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector Revisions

We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. MeiraGTx Holdings plc is one of the best biotech stocks to invest in. TheFly reported on April 1 that Evercore ISI analyst Gavin Clark-Gartner reduced the price t... Full story

Yahoo Finance • 4 months ago

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

MeiraGTx Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) MeiraGTx intends to immedi... Full story

Yahoo Finance • 4 months ago

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts Increases in Unstimulated Whole Saliv... Full story

Yahoo Finance • 4 months ago

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures. LONDO... Full story

Yahoo Finance • 9 months ago

MeiraGTx GAAP EPS of -$0.62 misses by $0.13, revenue of $0.41M misses by $6.56M

* MeiraGTx press release [https://seekingalpha.com/pr/20305977-meiragtx-reports-third-quarter-2025-financial-and-operational-results] (MGTX [https://seekingalpha.com/symbol/MGTX]): Q3 GAAP EPS of -$0.62 misses by $0.13. * Revenue of $0... Full story

Yahoo Finance • 9 months ago

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

MeiraGTx Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment of one of the most severe in... Full story

Yahoo Finance • 10 months ago

Stock market today: S&P 500, Nasdaq soar as Senate vote lifts hopes for end to US shutdown

Tech stocks led the market higher on Monday after the Senate took a big step toward ending the record-breaking government shutdown that has clouded the picture of the economy. The tech-heavy Nasdaq Composite (^IXIC) surged over 2%, while... Full story

Yahoo Finance • 10 months ago

Eli Lilly in pact with MeiraGTx to develop gene therapies for eye diseases

[Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals.] jetcityimage/iStock Editorial via Getty Images MeiraGTx (MGTX [https://seekingalpha.com/symbol/MGTX]) shares added ~18% in the premarket on Monday afte... Full story

Yahoo Finance • 10 months ago

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology... Full story

Yahoo Finance • last year

MeiraGTx CFO Giroux sells $204k in shares

Richard Giroux, Chief Financial Officer and Chief Operating Officer of MeiraGTx Holdings PLC (NASDAQ:MGTX), sold 24,000 ordinary shares of the company on July 22, 2025, according to a recent SEC filing. The shares were sold at a weighted... Full story

Yahoo Finance • last year

Meiragtx CEO Forbes sells $378k in shares

Alexandria Forbes, President and CEO of MeiraGTx Holdings PLC (NASDAQ:MGTX), sold 47,500 ordinary shares of the company on July 8, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a... Full story

Yahoo Finance • last year

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

LONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster presentations at the Amer... Full story